Biological and Pharmaceutical Bulletin · 2003 · 25 citations · 6 references
Life SciencesCell BiologyOncologyApoptosisCell DivisionCell ProliferationCancer CytogeneticsCell Cycle PharmacologyCell Division InhibitionCytotoxicity EvaluationMitotic InhibitorsCancer Cell Proliferation InhibitionCardiac GlycosidesCell Cycle AnalysisCell Cycle Arrest MechanismsFlow Cytometric AnalysisG1 Cell-cycle ArrestMitosis-related CytotoxicityTherapeutic Growth Inhibition
We have examined the cytotoxic effect of rhodexin A isolated from the extract of Rhodea japonica on human leukemia K562 cells using a flow cytometer and compared it with that of ouabain. Rhodexin A at 30 nM started to attenuate growth without affecting viability and further increases in the concentration of rhodexin A (100 nM or more) completely inhibited growth with decreasing viability. Rhodexin A at 30-100 nM increased the G(2)M population, but decreased the G(0)G(1) population, suggesting cell cycle arrest in the G(2)M phase. Rhodexin A at 100 nM increased the number of cells with hypodiploid DNA, indicating that rhodexin A induced apoptosis. The potency of rhodexin A to inhibit growth was greater than that of ouabain. The results indicate that rhodexin A exerts a potent inhibitory action on the growth of human leukemia K562 cells by inducing cell cycle arrest and apoptosis. Rhodexin A may also be a candidate for cancer treatment because there have been clinical reports of tumor regression in patients taking cardiac glycosides.
6
Digitoxin is a potential anticancer agent for several types of cancer
Johan Haux · Medical Hypotheses · 1999 · 168 citations
Medicine, Oncology, Pharmacology +8
Is digitalis a therapy for breast carcinoma?
Björn Stenkvist · Oncology Reports · 1999 · 158 citations
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells
Senia Johansson, Petra Lindholm, Joachim Gullbo et al. · Anti-Cancer Drugs · 2001 · 120 citations
Medicine, Oncology, Pharmacology +13